Datawatch ANNOUNCES Alliance with ACL and 4 Stocks Enjoying 52-Week Highs

Datawatch Corp. (NASDAQ:DWCH) and ACL Services announced a strategic alliance which will provide audit, risk and compliance professionals with the enhanced ability to analyze data trapped in static reports like PDFs, HTML files, print files, and other content-rich data sources.The shares closed at $16.20, up $0.41 or 2.6% on the day. They have traded in a 52-week range of $4.70 to $16.15.

Don’t Miss: Google Takes This NEW Product Back to the Drawing Board.

Johnson & Johnson (NYSE:JNJ): Pharmacyclics (NASDAQ:PCYC) announced that the international Phase III randomized, multicenter, open-label clinical trial, RESONATE, or PCYC-1112, of ibrutinib compared to ofatumumab for patients suffering from relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, or CLL/SLL, initiated by Pharmacyclics has enrolled its fifth patient. The enrollment of the fifth patient has also triggered a $50 million milestone payment obligation from Janssen Biotech, which is one of the Janssen Pharmaceutical Companies of Johnson & Johnson and is the worldwide collaborator on ibrutinib in oncology. As Pharmacyclics or Janssen continue Phase III trials in specific indications and enroll the 5th patient, more milestone payments of $50 million could be triggered reaching a total of $250 million. The company predicts another Phase III trial milestone payment during calendar 2013. “Data from patients with CLL/SLL observed in our Phase Ib/II program provide strong rationale for initiating the Phase III registration trial,” stated Lori A. Kunkel, M.D. Chief Medical Officer. A Phase III trial of ibrutinib in frontline elderly CLL/SLL patients as a single agent and the trials in mantle cell lymphoma, are all expected to begin in late 2012 or early 2013. The shares closed at $69.38, up $0.16 or 0.23% on the day. They have traded in a 52-week range of $59.08 to $69.70.

Phillips 66 Common (PSX) anticipates funding the repurchases mostly with cash generated by its operations. Shares of stock repurchased is to be held as treasury shares. The shares closed at $38.36, up $0.76 or 2.02% on the day. They have traded in a 52-week range of $28.75 to $38.36.

Stratasys (NASDAQ:SSYS) reports a Q2 adjusted EPS of 32c, consensus 32c. The shares closed at $59.82, down $1.46 or 2.38% on the day. They have traded in a 52-week range of $17.88 to $63.95.

Don’t Miss: Apple Talent Getting POACHED.

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.